پریسا باقری - Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
فرهاد ذاکر - Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
محمد هادی صادقیان - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
سوده نامجو - Department of Hematology and Blood Banking, School of Allied Medical Sciences, Iran University of Medical Sciences, Tehran, Iran
سعیده حاجبی خانیکی - Student Research Committee, Department of Biostatistics, School of Health, Mashhad University of Medical Sciences, Mashhad, Iran
Zahra Chehreghani - Department of Hematology and Blood Banking, Faculty of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran
مریم شیخی - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
حسین آیت اللهی - Cancer Molecular Pathology Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Background and Aims: DNA methyltransferase۳A (DNMT۳A) is necessary for the adjustment of gene expression, and the mutations in the DNMT۳A gene are reported in a variety of leukemia cases. DNMT۳A mutations are during cancer progression and cause poor prognosis in many leukemias. Thus, this gene can be a target for new treatments. This study aimed to examine the distribution of DNMT۳A mutations in Iranian acute leukemia patients. Materials and Methods: In this study, diagnostic samples from ۴۵ patients with de novo acute leukemia, including ۲۲ acute myeloid leukemia (AML) patients, and ۲۳ acute leukemia lymphoblastic (ALL) patients were screened, from April ۲۰۱۷ to March ۲۰۱۸ for the incidence of DNMT۳A mutations by polymerase chain reaction and direct sequencing. Results: A total of ۲ (۹.۱%) AML cases and ۱ (۴.۳۴%) ALL cases were found to have the DNMT۳A R۸۸۲H mutation. It was found that a total of ۲۲.۷% and ۲۱.۷% of patients with AML and ALL had polymorphism rs۳۶۸۵۱۶۵۴۳, respectively. DNMT۳A mutations were considerably associated with higher age in AML patients. Conclusions: The findings suggest that the DNMT۳A mutations are probably a new biomarker in the early examination and treatment of acute leukemia, even though further studies are needed.

Acute lymphoblastic leukemia, Acute myeloid leukemia, DNMT۳A mutation, لوسمی لنفوئیدی حاد, لوسمی میلوئیدی حاد, جهش DNMT۳A